Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years

R. Gale, F. Penning-van Beest, M. van Herk-Sukel, J. W. Lammers, R. Herings (Rotterdam, Utrecht, Netherlands; West Sessex, United Kingdom)

Source: Annual Congress 2009 - Drug effects in COPD
Session: Drug effects in COPD
Session type: Thematic Poster Session
Number: 2008
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Gale, F. Penning-van Beest, M. van Herk-Sukel, J. W. Lammers, R. Herings (Rotterdam, Utrecht, Netherlands; West Sessex, United Kingdom). Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years. Eur Respir J 2009; 34: Suppl. 53, 2008

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015



Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 240s
Year: 2002

Effects of esomeprazole 40 mg twice-daily in adults with moderate to severe asthma who had been treated previously with inhaled steroids and long-acting β2-agonists
Source: Eur Respir J 2005; 26: Suppl. 49, 278s
Year: 2005

Annual systemic and inhaled corticosteroid exposures in US patients =4 years with asthma
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid
Source: Eur Respir J 2002; 20: Suppl. 38, 113s
Year: 2002

The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004

Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017

Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020


Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007


Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016